Physician profile
Jan Drappatz
NPI 1831275205
$16,945.86
in general payments reported to CMS, 2019-2025
11 companies · $13K in 2025
The $13K reported for 2025 was more than what 91% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $309 · 2020: $2,704 · 2022: $596 · 2023: $231 · 2024: $36.72 · 2025: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $13K · Food and Beverage: $380 · Travel and Lodging: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $12,806.14 |
| Food and Beverage | $380.18 |
| Travel and Lodging | $150.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Servier Pharmaceuticals LLC | $12,999.88 | 2025 | |
| Novocure INC. | $1,840.93 | 2020-2024 | Optune |
| Bayer Healthcare Pharmaceuticals INC. | $900.00 | 2020 | |
| Medtronic, INC. | $595.83 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $326.61 | 2019-2025 | |
| Agios Pharmaceuticals, INC. | $184.60 | 2019 | |
| Merck Sharp & Dohme LLC | $98.01 | 2023 | Welireg |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jan Drappatz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.